Solid Biosciences (SLDB) Net Cash Flow (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,020.96% |
| Dec 31, 2025 | 98.20% |
| Sep 30, 2025 | -8.12% |
| Jun 30, 2025 | -155.01% |
| Mar 31, 2025 | 722.19% |
| Dec 31, 2024 | 150.45% |
| Sep 30, 2024 | -45.26% |
| Jun 30, 2024 | -149.69% |
| Mar 31, 2024 | 74.39% |
| Dec 31, 2023 | 158.73% |
| Sep 30, 2023 | 43.81% |
| Jun 30, 2023 | -917.02% |
| Mar 31, 2023 | -91.29% |
| Dec 31, 2022 | 2,026.41% |
| Sep 30, 2022 | 92.68% |
| Jun 30, 2022 | -813.00% |
| Mar 31, 2022 | 12.88% |
| Dec 31, 2021 | 110.30% |
| Sep 30, 2021 | -37.66% |
| Jun 30, 2021 | -158.07% |
| Mar 31, 2021 | 9,022.13% |
| Dec 31, 2020 | 107.97% |
| Sep 30, 2020 | -22.74% |
| Jun 30, 2020 | 44.23% |
| Mar 31, 2020 | -22.38% |
| Dec 31, 2019 | -22.25% |
| Sep 30, 2019 | -607.97% |
| Jun 30, 2019 | 93.33% |
| Mar 31, 2019 | 24.15% |
| Dec 31, 2018 | -155.77% |
| Sep 30, 2018 | 12.24% |
| Jun 30, 2018 | -116.84% |
| Mar 31, 2018 | 205.50% |
| Dec 31, 2017 | 308.87% |
| Sep 30, 2017 | -613.58% |
| Jun 30, 2017 | -84.04% |